You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for New Drug Application (NDA): 212295


✉ Email this page to a colleague

« Back to Dashboard


NDA 212295 describes BYFAVO, which is a drug marketed by Acacia and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug. Additional details are available on the BYFAVO profile page.

The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this compound. Additional details are available on the remimazolam besylate profile page.
Summary for 212295
Tradename:BYFAVO
Applicant:Acacia
Ingredient:remimazolam besylate
Patents:11
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 212295
Generic Entry Date for 212295*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 212295
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BYFAVO remimazolam besylate POWDER;INTRAVENOUS 212295 NDA Acacia Pharma, Ltd. 71390-011 71390-011-11 10 VIAL in 1 CARTON (71390-011-11) / 8 mL in 1 VIAL (71390-011-00)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrengthEQ 20MG BASE/VIAL
Approval Date:Oct 6, 2020TE:RLD:Yes
Regulatory Exclusivity Expiration:Oct 6, 2025
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:10,052,334Patent Expiration:Nov 7, 2031Product Flag?Substance Flag?Delist Request?
Patented Use:USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
Patent:10,195,210Patent Expiration:Nov 7, 2031Product Flag?Substance Flag?Delist Request?
Patented Use:USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.